Johnson & Johnson model projects lower lifetime costs with Impella versus balloon pump in high-risk PCI

By Public Technologies
  • Johnson & Johnson will present 26 Impella heart pump abstracts at TCT 2026, running Oct. 31-Nov. 3 in San Diego.
  • A model projects lower lifetime healthcare costs and better quality-adjusted survival versus intra-aortic balloon pumps for heart failure patients undergoing high-risk PCI.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk